Acute Treatments: Future Developments

References

• Hamel E. 5-HT1D receptors: pharmacology and therapeutic potential. Serotonin 1996;1:19–29
   Google Scholar
• Dingemanse J, Soubrouillard C, Paris J, et al. Pronounced effect of caprylocaproyl macroglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor antagonist. Clin Pharmacol Ther 2000;68: 114–21
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Gray JA, Soubrouillard C, et al. Pilot efficacy study of IS-159, a peptide serotonin 1B/1D receptor agonist, after intranasal application in migraineurs. Presented at the 9th Congress of the International Headache Society, Barcelona, Spain, June 22–26, 1999
   Google Scholar
• John GW, Pauwels PJ, Perez M, et al. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5HT1B/D receptors in models relevant to migraine. J Pharmacol Exp Ther 1999;290: 83–95
   PubMed Web of Science ®Google Scholar
• Pauwels PJ, John GW. Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol 1999;22:123–6
   PubMed Web of Science ®Google Scholar
• Ma QP. Co-localization of 5-HT (1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001; 12:1589–91
   PubMed Web of Science ®Google Scholar
• Hill RG, Salt TE. Differentiation of excitatory amino acid receptors in the rat caudal trigeminal nucleus: a microiontophoretic study. Neuropharmacology 1982;21: 385–90
   PubMed Web of Science ®Google Scholar
• Sahara Y, Noro N, Iida Y, et al. Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 1997;17: 6611–20
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Vos BP, Strassman AM. The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain. Pain 1993;54:301–7
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Sanchez del Rio M, Waeber C, et al. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 1999;127:623–30
   PubMed Web of Science ®Google Scholar
• Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves N-Methyl-D-Aspartate and Non-N-Methyl-D-Aspartate glutamate receptors. Neuro-science 1999;90:1371–6
   Google Scholar
• Johnson KW, Dieckman DK, Phebus LA, et al. GluR5 antagonists as novel migraine therapies (abstract). Cephalalgia 2001;21: 268
   Google Scholar
• Ferrari MD, Odink J, Bos KD, et al. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990;40:1582–6
   PubMed Web of Science ®Google Scholar
• Alam Z, Coombes N, Waring RH, et al. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci 1998;156:102–6
   PubMed Web of Science ®Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614–24
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain 1999;Suppl. 6:S141–7
   Google Scholar
• Kaube H, Herzog J, Kaufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000;55:139–41
   PubMed Web of Science ®Google Scholar
• Simmons RM, Li DL, Hoo KH, et al. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 1998;37: 25–36
   PubMed Web of Science ®Google Scholar
• Sang CN, Hostetter MP, Gracely RH, et al. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyper-algesia but not pain in normal skin in humans. Anesthesiology 1998;89: 1060–7
   PubMed Web of Science ®Google Scholar
• Gilron I, Max MB, Lee G, et al. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/ kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther 2000;68: 320–7
   PubMed Web of Science ®Google Scholar
• Ramadan N, Sang C, Chappell A, et al. IV LY293558, an AMPA/KA receptor antagonist, is effective in migraine (abstract). Cephalalgia 2001;21: 267–8
   Google Scholar
• Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509–23
   PubMed Web of Science ®Google Scholar
• Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001;53:167–78
   PubMed Web of Science ®Google Scholar
• Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129: 420–3
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Sams A, Jansen-Olesen I, et al. Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol 2001;415:39–44
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Olesen J. Nitric oxide theory of migraine. Clin Neurosci 1998;5:28–33
   PubMedGoogle Scholar
• Tassorelli C, Joseph SA, Buzzi MG, Nappi G. The effects on central nervous system of nitroglycerin – putative mechanisms and mediators. Prog Neurobiol 1999;57:607–24
   PubMed Web of Science ®Google Scholar
• Reuter U, Bolay H, Chiarugi A, et al. Nitroglycerin infusion causes a delayed inflammatory response in dura mater (abstract). Cephalalgia 2001;21:276
   Google Scholar
• Olesen J, Iversen HK, Thomsen LL. Nitric oxide super-sensitivity. A possible molecular mechanism of migraine pain. Neuroreport 1993;4:1027–30
   PubMed Web of Science ®Google Scholar
• Wei EP. Moskowitz MA, Baccalini P, Kontos HA. Calcitonin gene related peptide mediates nitroglycerin and sodium nitroprusside induced vasodilation in feline cerebral arteries. Circ Res 1992;70:1313–19
   PubMed Web of Science ®Google Scholar
• Read SJ, Smith MI, Hunter AJ, Parsons AA. The dynamics of nitric oxide release measured directly and in real time following repeated waves of cortical spreading depression in the anesthetized cat. Neurosci Lett 1997;232:127–30
   PubMed Web of Science ®Google Scholar
• Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition in migraine. Lancet 1997;349:401–2
   PubMed Web of Science ®Google Scholar
• Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998;18: 27–31
   Google Scholar
• Diamond et al. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 2000;20:597–602
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Bland-Ward PA, Carruthers AA, et al. Inhibition of trigeminal nociceptive afferents by adenosine A1 receptor activation: a novel approach towards the design of new anti-migraine compounds. (Abstract). Cephalalgia 2001;21
   PubMedGoogle Scholar
• Read SJ, Smith MI, Hunter AJ, et al. SB220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of spreading depression in the anaesthetised cat. Cephalalgia 2000;20: 282
   Google Scholar